Lamisil DermGel gel

Land: Armenia

Språk: engelsk

Kilde: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

Aktiv ingrediens:

terbinafine

Tilgjengelig fra:

GlaxoSmithKline Consumer Healthcare S.A.

ATC-kode:

D01AE15

INN (International Name):

terbinafine

Dosering :

10mg/g

Legemiddelform:

gel

Enheter i pakken:

15g aluminium tube

Resept typen:

OTC

Autorisasjon status:

Registered

Autorisasjon dato:

2020-01-09

Preparatomtale

GSK Consumer Healthcare S.A.
CH-1260 Nyon, Switzerland
Global Drug Regulatory Affairs
LAMISIL DERMGEL
Terbinafine
SUMMARY OF PRODUCT CHARACTERISTICS
Property of GSK Consumer Healthcare S.A.
Confidential
May not be used, divulged, published or otherwise disclosed
without the consent of GSK Consumer Healthcare S.A.
GSK Consumer Healthcare S.A.
CONFIDENTIAL
Page 2
Summary of Product Characteristics
LamisilDermgel 1% Gel
CONTENTS
1.
NAME OF THE MEDICINAL PRODUCT
................................................................................
3
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
...................................................... 3
3.
PHARMACEUTICAL FORM
....................................................................................................
3
4.
CLINICAL PARTICULARS
......................................................................................................
3
4.1.
Therapeutic indications
..................................................................................................
3
4.2.
Posology and method of administration
.........................................................................
3
4.3.
Contra-indications
..........................................................................................................
4
4.4.
Special warnings and precautions for use
......................................................................
4
4.5.
Interactions with other medicinal products and other forms of
interaction ................... 4
4.6.
Pregnancy and lactation
..................................................................................................
4
4.7.
Effects on ability to drive and use machines
.................................................................. 4
4.8.
Undesirable effects
.........................................................................................................
4
4.9.
Overdose
.........................................................................................................................
5
5.
PHARMACOLOGICAL PROPE